The consequences of EMAST and MSH3 dysfunction for patient care include an association with advanced stage colorectal cancer as well as reduced survival; it is not clear what the consequences are amongst patients with non-cancer inflamed tissue other than perhaps priming the tissue towards neoplasia [30], but this is speculative. This evidence concerns the gene MSH3 and cancer.